Bristol-Myers Receivables Trend from 2010 to 2021

BMY -  USA Stock  

USD 68.15  0.58  0.84%

Bristol-Myers Squibb Trade and Non Trade Receivables yearly trend continues to be fairly stable with very little volatility. Trade and Non Trade Receivables will likely drop to about 7.4 B in 2021. During the period from 2010 to 2021, Bristol-Myers Squibb Trade and Non Trade Receivables regression line of anual values had slope of 488,808,612 and arithmetic mean of  5,208,903,509. Bristol-Myers Squibb Direct Expenses is fairly stable at the moment as compared to the past year. Bristol-Myers Squibb reported Direct Expenses of 11.77 Billion in 2020. Net Income to Non Controlling Interests is likely to rise to about 20.5 M in 2021, whereas Consolidated Income is likely to drop (9.2 B) in 2021.

Search Historical Trends 

Check Bristol-Myers Squibb financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol-Myers main balance sheet or income statement drivers, such as Direct Expenses of 12.7 B, Cost of Revenue of 9.6 B or Gross Profit of 25.3 B, as well as many exotic indicators such as Interest Coverage of 10.64, Long Term Debt to Equity of 1.38 or Calculated Tax Rate of 24.75. Bristol-Myers financial statements analysis is a perfect complement when working with Bristol-Myers Squibb Valuation or Volatility modules. It can also supplement various Bristol-Myers Squibb Technical models. Continue to the analysis of Bristol-Myers Squibb Correlation against competitors.

Bristol-Myers Receivables Breakdown

Showing smoothed Receivables of Bristol-Myers Squibb with missing and latest data points interpolated. Bristol-Myers Squibb's Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol-Myers Squibb's overall financial position and show how it may be relating to other accounts over time.
Receivables10 Years Trend
Slightly volatile

Bristol-Myers Receivables Regression Statistics

Arithmetic Mean 4,480,260,965
Geometric Mean 3,814,979,013
Coefficient Of Variation 59.69
Mean Deviation 2,232,637,792
Median 4,013,000,000
Standard Deviation 2,674,357,781
Range 7,265,131,579
R-Value 0.93
R-Squared 0.87
Significance 0.00000854
Slope 693,099,466

Bristol-Myers Receivables History

20112.4 B
20121.9 B
20142.3 B
20153.2 B
20175.1 B
20185.4 B
20197.7 B
20208.5 B
20219.2 B

Other Fundumenentals of Bristol-Myers Squibb

Bristol-Myers Squibb Receivables component correlations

About Bristol-Myers Squibb Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol-Myers Squibb income statement, its balance sheet, and the statement of cash flows. Bristol-Myers Squibb investors use historical funamental indicators, such as Bristol-Myers Squibb's Receivables, to determine how well the company is positioned to perform in the future. Although Bristol-Myers Squibb investors may use each financial statement separately, they are all related. The changes in Bristol-Myers Squibb's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol-Myers Squibb's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol-Myers Squibb Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol-Myers Squibb. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Receivables8.5 B9.2 B
Trade and Non Trade Receivables8.5 B7.4 B
Receivables Turnover 5.24  6.53 
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 30250 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol-Myers Squibb without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run My Watchlist Analysis Now


My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module

Pair Trading with Bristol-Myers Squibb

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.

Bristol-Myers Squibb Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol-Myers Squibb and Horizon Therapeutics. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Bristol-Myers Squibb Correlation against competitors. Note that the Bristol-Myers Squibb information on this page should be used as a complementary analysis to other Bristol-Myers Squibb's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Bristol-Myers Stock analysis

When running Bristol-Myers Squibb price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol-Myers that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol-Myers Squibb's value that differs from its market value or its book value, called intrinsic value, which is Bristol-Myers Squibb's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol-Myers Squibb's market value can be influenced by many factors that don't directly affect Bristol-Myers Squibb underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol-Myers Squibb's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol-Myers Squibb value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.